{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T21:58:46Z","timestamp":1778191126364,"version":"3.51.4"},"reference-count":51,"publisher":"Portland Press Ltd.","issue":"2","content-domain":{"domain":["portlandpress.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2019,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Gaucher disease (GD) is a rare lysosomal storage disorder caused by mutations in the GBA1 gene, encoding the lysosome-resident glucocerebrosidase enzyme involved in the hydrolysis of glucosylceramide. The discovery of an association between mutations in GBA1 and the development of synucleinopathies, including Parkinson disease, has directed attention to glucocerebrosidase as a potential therapeutic target for different synucleinopathies. These findings initiated an exponential growth in research and publications regarding the glucocerebrosidase enzyme. The use of various commercial and custom-made glucocerebrosidase antibodies has been reported, but standardized in-depth validation is still not available for many of these antibodies. This work details the evaluation of several previously reported glucocerebrosidase antibodies for western blot analysis, tested on protein lysates of murine gba+\/+ and gba\u2212\/\u2212 immortalized neurons and primary human wild-type and type 2 GD fibroblasts.<\/jats:p>","DOI":"10.1042\/bcj20180708","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T19:36:31Z","timestamp":1545420991000},"page":"261-274","update-policy":"https:\/\/doi.org\/10.1042\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Validation of anti-glucocerebrosidase antibodies for western blot analysis on protein lysates of murine and human cells"],"prefix":"10.1042","volume":"476","author":[{"given":"Wenduo","family":"Qi","sequence":"first","affiliation":[{"name":"Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brad A.","family":"Davidson","sequence":"additional","affiliation":[{"name":"Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Nguyen","sequence":"additional","affiliation":[{"name":"Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taylor","family":"Lindstrom","sequence":"additional","affiliation":[{"name":"Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Grey","sequence":"additional","affiliation":[{"name":"Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Burnett","sequence":"additional","affiliation":[{"name":"Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elma","family":"Aflaki","sequence":"additional","affiliation":[{"name":"Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3019-8500","authenticated-orcid":false,"given":"Ellen","family":"Sidransky","sequence":"additional","affiliation":[{"name":"Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy","family":"Westbroek","sequence":"additional","affiliation":[{"name":"Section on Molecular Neurogenetics, Medical Genetics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, U.S.A."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"288","published-online":{"date-parts":[[2019,1,25]]},"reference":[{"key":"2021112217545126100_BCJ-2018-0708C1","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1615\/CritRevOncog.2013006060","article-title":"Gaucher disease: a comprehensive review","volume":"18","year":"2013","journal-title":"Crit. Rev. Oncog."},{"key":"2021112217545126100_BCJ-2018-0708C2","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1056\/NEJMoa0901281","article-title":"Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease","volume":"361","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"2021112217545126100_BCJ-2018-0708C3","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1093\/brain\/awu002","article-title":"Glucocerebrosidase is shaking up the synucleinopathies","volume":"137","year":"2014","journal-title":"Brain"},{"key":"2021112217545126100_BCJ-2018-0708C4","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nmeth.3995","article-title":"A proposal for validation of antibodies","volume":"13","year":"2016","journal-title":"Nat. Methods"},{"key":"2021112217545126100_BCJ-2018-0708C5","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/nbt0710-650","article-title":"Minimum information about a protein affinity reagent (MIAPAR)","volume":"28","year":"2010","journal-title":"Nat. Biotechnol."},{"key":"2021112217545126100_BCJ-2018-0708C6","doi-asserted-by":"publisher","first-page":"117739011875746","DOI":"10.1177\/1177390118757462","article-title":"Ten basic rules of antibody validation","volume":"13","year":"2018","journal-title":"Anal. Chem. Insights"},{"key":"2021112217545126100_BCJ-2018-0708C7","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4137\/ACI.S31614","article-title":"Quality issues of research antibodies","volume":"11","year":"2016","journal-title":"Anal. Chem. Insights"},{"key":"2021112217545126100_BCJ-2018-0708C8","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1038\/527545a","article-title":"Antibody anarchy: a call to order","volume":"527","year":"2015","journal-title":"Nature"},{"key":"2021112217545126100_BCJ-2018-0708C9","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/521274a","article-title":"Reproducibility crisis: blame it on the antibodies","volume":"521","year":"2015","journal-title":"Nature"},{"key":"2021112217545126100_BCJ-2018-0708C10","doi-asserted-by":"publisher","first-page":"e148","DOI":"10.7717\/peerj.148","article-title":"On the reproducibility of science: unique identification of research resources in the biomedical literature","volume":"1","year":"2013","journal-title":"PeerJ"},{"key":"2021112217545126100_BCJ-2018-0708C11","doi-asserted-by":"publisher","first-page":"161","DOI":"10.12688\/f1000research.10851.1","article-title":"The challenges with the validation of research antibodies","volume":"6,","year":"2017","journal-title":"F1000Res."},{"key":"2021112217545126100_BCJ-2018-0708C12","doi-asserted-by":"publisher","first-page":"232","DOI":"10.12688\/f1000research.4966.2","article-title":"Commercial antibodies and their validation","volume":"3","year":"2014","journal-title":"F1000Res."},{"key":"2021112217545126100_BCJ-2018-0708C13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1038\/518027a","article-title":"Reproducibility: standardize antibodies used in research","volume":"518","year":"2015","journal-title":"Nature"},{"key":"2021112217545126100_BCJ-2018-0708C14","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/518483c","article-title":"Antibodies: validate recombinants too","volume":"518","year":"2015","journal-title":"Nature"},{"key":"2021112217545126100_BCJ-2018-0708C15","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/518483b","article-title":"Antibodies: the solution is validation","volume":"518","year":"2015","journal-title":"Nature"},{"key":"2021112217545126100_BCJ-2018-0708C16","doi-asserted-by":"publisher","first-page":"15840","DOI":"10.1038\/ncomms15840","article-title":"Insufficient antibody validation challenges oestrogen receptor beta research","volume":"8","year":"2017","journal-title":"Nat. Commun."},{"key":"2021112217545126100_BCJ-2018-0708C17","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/biot.201300341","article-title":"Antibody performance in western blot applications is context-dependent","volume":"9","year":"2014","journal-title":"Biotechnol. J."},{"key":"2021112217545126100_BCJ-2018-0708C18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1242\/dmm.024588","article-title":"A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease","volume":"9","year":"2016","journal-title":"Dis. Model. Mech."},{"key":"2021112217545126100_BCJ-2018-0708C19","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/0003-2697(86)90043-6","article-title":"A procedure for the rapid purification in high yield of human glucocerebrosidase using immunoaffinity chromatography with monoclonal antibodies","volume":"154","year":"1986","journal-title":"Anal. Biochem."},{"key":"2021112217545126100_BCJ-2018-0708C20","doi-asserted-by":"publisher","first-page":"5607","DOI":"10.1073\/pnas.79.18.5607","article-title":"Mutations of glucocerebrosidase: discrimination of neurologic and non-neurologic phenotypes of Gaucher disease","volume":"79","year":"1982","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112217545126100_BCJ-2018-0708C21","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1038\/nchembio.466","article-title":"Ultrasensitive in situ visualization of active glucocerebrosidase molecules","volume":"6","year":"2010","journal-title":"Nat. Chem. Biol."},{"key":"2021112217545126100_BCJ-2018-0708C22","doi-asserted-by":"publisher","first-page":"3454","DOI":"10.1002\/jcp.25807","article-title":"Impact of lysosomal storage disorders on biology of mesenchymal stem cells: evidences from in vitro silencing of glucocerebrosidase (GBA) and alpha-galactosidase A (GLA) enzymes","volume":"232","year":"2017","journal-title":"J. Cell. Physiol."},{"key":"2021112217545126100_BCJ-2018-0708C23","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1093\/hmg\/ddy105","article-title":"Acid ceramidase inhibition ameliorates \u03b1-synuclein accumulation upon loss of GBA1 function","volume":"27","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"2021112217545126100_BCJ-2018-0708C24","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ebiom.2016.08.004","article-title":"Association between progranulin and Gaucher disease","volume":"11","year":"2016","journal-title":"EBioMedicine"},{"key":"2021112217545126100_BCJ-2018-0708C25","doi-asserted-by":"publisher","first-page":"1751","DOI":"10.12688\/f1000research.12090.2","article-title":"Dermal fibroblasts from patients with Parkinson's disease have normal GCase activity and autophagy compared to patients with PD and GBA mutations","volume":"6","year":"2018","journal-title":"F1000Res."},{"key":"2021112217545126100_BCJ-2018-0708C26","doi-asserted-by":"publisher","first-page":"5914","DOI":"10.1021\/jacs.7b13003","article-title":"\u03b2-Glucocerebrosidase modulators promote dimerization of \u03b2-glucocerebrosidase and reveal an allosteric binding site","volume":"140","year":"2018","journal-title":"J. Am. Chem. Soc."},{"key":"2021112217545126100_BCJ-2018-0708C27","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1111\/j.1471-4159.2012.07879.x","article-title":"Glucocerebrosidase mutations alter the endoplasmic reticulum and lysosomes in Lewy body disease","volume":"123","year":"2012","journal-title":"J. Neurochem."},{"key":"2021112217545126100_BCJ-2018-0708C28","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1073\/pnas.1700465115","article-title":"GBA1 deficiency negatively affects physiological \u03b1-synuclein tetramers and related multimers","volume":"115","year":"2018","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112217545126100_BCJ-2018-0708C29","doi-asserted-by":"publisher","first-page":"1696","DOI":"10.1093\/hmg\/ddy075","article-title":"Modulation of \u03b2-glucocerebrosidase increases \u03b1-synuclein secretion and exosome release in mouse models of Parkinson's disease","volume":"27","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"2021112217545126100_BCJ-2018-0708C30","doi-asserted-by":"publisher","first-page":"9617","DOI":"10.1523\/JNEUROSCI.1525-17.2017","article-title":"Glucosylsphingosine promotes \u03b1-synuclein pathology in mutant GBA-associated Parkinson's disease","volume":"37","year":"2017","journal-title":"J. Neurosci."},{"key":"2021112217545126100_BCJ-2018-0708C31","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ymgme.2017.11.001","article-title":"Glucocerebrosidase haploinsufficiency in A53T \u03b1-synuclein mice impacts disease onset and course","volume":"122","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"2021112217545126100_BCJ-2018-0708C32","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1073\/pnas.1520335113","article-title":"\u03b1-Synuclein\u2013induced lysosomal dysfunction occurs through disruptions in protein trafficking in human midbrain synucleinopathy models","volume":"113","year":"2016","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112217545126100_BCJ-2018-0708C33","doi-asserted-by":"publisher","first-page":"e0143854","DOI":"10.1371\/journal.pone.0143854","article-title":"Lysosomal enzyme glucocerebrosidase protects against A\u03b21-42 oligomer-induced neurotoxicity","volume":"10","year":"2015","journal-title":"PLoS ONE"},{"key":"2021112217545126100_BCJ-2018-0708C34","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1016\/j.bbrc.2013.10.145","article-title":"Cholesterol glucosylation is catalyzed by transglucosylation reaction of \u03b2-glucosidase 1","volume":"441","year":"2013","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"2021112217545126100_BCJ-2018-0708C35","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/1750-1172-9-86","article-title":"Parkin-mediated ubiquitination of mutant glucocerebrosidase leads to competition with its substrates PARIS and ARTS","volume":"9","year":"2014","journal-title":"Orphanet. J. Rare Dis."},{"key":"2021112217545126100_BCJ-2018-0708C36","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.bcmd.2012.10.007","article-title":"Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase, blood cells","volume":"50","year":"2013","journal-title":"Mol. Dis."},{"key":"2021112217545126100_BCJ-2018-0708C37","doi-asserted-by":"publisher","first-page":"e0119141","DOI":"10.1371\/journal.pone.0119141","article-title":"Tool compounds robustly increase turnover of an artificial substrate by glucocerebrosidase in human brain lysates","volume":"10","year":"2015","journal-title":"PLoS ONE"},{"key":"2021112217545126100_BCJ-2018-0708C38","doi-asserted-by":"publisher","first-page":"2649","DOI":"10.1016\/J.NEUROBIOLAGING.2015.06.004","article-title":"Increased oligomerization and phosphorylation of \u03b1-synuclein are associated with decreased activity of glucocerebrosidase and protein phosphatase 2A in aging monkey brains","volume":"36","year":"2015","journal-title":"Neurobiol. Aging"},{"key":"2021112217545126100_BCJ-2018-0708C39","doi-asserted-by":"publisher","first-page":"fj201701512RR","DOI":"10.1096\/fj.201701512RR","article-title":"A lysosome-plasma membrane-sphingolipid axis linking lysosomal storage to cell growth arrest","year":"2018","journal-title":"FASEB J."},{"key":"2021112217545126100_BCJ-2018-0708C40","doi-asserted-by":"publisher","first-page":"12702","DOI":"10.1038\/s41598-017-12973-5","article-title":"The GBAP1 pseudogene acts as a ceRNA for the glucocerebrosidase gene GBA by sponging miR-22-3p","volume":"7","year":"2017","journal-title":"Sci. Rep."},{"key":"2021112217545126100_BCJ-2018-0708C41","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1093\/brain\/awu020","article-title":"Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells","volume":"137","year":"2014","journal-title":"Brain"},{"key":"2021112217545126100_BCJ-2018-0708C42","doi-asserted-by":"publisher","first-page":"21665","DOI":"10.1073\/pnas.1014376107","article-title":"Decreased glucocerebrosidase activity in Gaucher disease parallels quantitative enzyme loss due to abnormal interaction with TCP1 and c-Cbl","volume":"107","year":"2010","journal-title":"Proc. Natl Acad. Sci. U.S.A."},{"key":"2021112217545126100_BCJ-2018-0708C43","doi-asserted-by":"publisher","first-page":"7693","DOI":"10.1523\/JNEUROSCI.0628-16.2016","article-title":"Activation of glucocerebrosidase reduces pathological \u03b1-synuclein and restores lysosomal function in Parkinson's patient midbrain neurons","volume":"36","year":"2016","journal-title":"J. Neurosci."},{"key":"2021112217545126100_BCJ-2018-0708C44","doi-asserted-by":"publisher","first-page":"1830","DOI":"10.1021\/acschembio.7b00276","article-title":"Stabilization of glucocerebrosidase by active site occupancy","volume":"12","year":"2017","journal-title":"ACS Chem. Biol."},{"key":"2021112217545126100_BCJ-2018-0708C45","doi-asserted-by":"publisher","first-page":"2299","DOI":"10.1194\/jlr.M079376","article-title":"In situ visualization of glucocerebrosidase in human skin tissue: zymography versus activity-based probe labeling","volume":"58","year":"2017","journal-title":"J. Lipid Res."},{"key":"2021112217545126100_BCJ-2018-0708C46","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1016\/j.placenta.2014.12.001","article-title":"Increased glucocerebrosidase expression and activity in preeclamptic placenta","volume":"36","year":"2015","journal-title":"Placenta"},{"key":"2021112217545126100_BCJ-2018-0708C47","doi-asserted-by":"publisher","first-page":"e130","DOI":"10.1038\/mtna.2013.57","article-title":"HIV tat domain improves cross-correction of human galactocerebrosidase in a gene- and flanking sequence-dependent manner","volume":"2","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"2021112217545126100_BCJ-2018-0708C48","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1080\/15476286.2014.996085","article-title":"Identification of miRNAs that modulate glucocerebrosidase activity in Gaucher disease cells","volume":"11","year":"2014","journal-title":"RNA Biol."},{"key":"2021112217545126100_BCJ-2018-0708C49","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1016\/j.ymgme.2011.06.008","article-title":"Aggregation of \u03b1-synuclein in brain samples from subjects with glucocerebrosidase mutations","volume":"104","year":"2011","journal-title":"Mol. Genet. Metab."},{"key":"2021112217545126100_BCJ-2018-0708C50","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1002\/humu.21566","article-title":"A mutation in SCARB2 is a modifier in Gaucher disease","volume":"32","year":"2011","journal-title":"Hum. Mutat."},{"key":"2021112217545126100_BCJ-2018-0708C51","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1016\/j.chembiol.2014.06.008","article-title":"ERdj3 is an endoplasmic reticulum degradation factor for mutant glucocerebrosidase variants linked to Gaucher's disease","volume":"21","year":"2014","journal-title":"Chem. Biol."}],"container-title":["Biochemical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/476\/2\/261\/849047\/bcj-2018-0708.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/portlandpress.com\/biochemj\/article-pdf\/476\/2\/261\/849047\/bcj-2018-0708.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,23]],"date-time":"2021-11-23T02:23:14Z","timestamp":1637634194000},"score":1,"resource":{"primary":{"URL":"https:\/\/portlandpress.com\/biochemj\/article\/476\/2\/261\/219497\/Validation-of-anti-glucocerebrosidase-antibodies"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,25]]},"references-count":51,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,1,31]]}},"URL":"https:\/\/doi.org\/10.1042\/bcj20180708","relation":{},"ISSN":["0264-6021","1470-8728"],"issn-type":[{"value":"0264-6021","type":"print"},{"value":"1470-8728","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,1,25]]}}}